Cantor Fitzgerald raised the firm’s price target on Eli Lilly to $550 from $485 and keeps an Overweight rating on the shares. Eli Lilly reported several better than anticipated data readouts, including for orforglipron, retatrutide, and donanemab Phase 3 trials, with the firm’s analyst saying the peak sales potential of the new drugs is still underappreciated.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LLY:
- Here’s 2023’s Best-Performing Actively-Managed ETF
- Lilly weight loss drug shows potential best-in-class profile, says JPMorgan
- Pharmaceutical companies are developing drugs to surpass Ozempic, WSJ reports
- Eli Lilly price target raised to $500 from $420 at Barclays
- Eli Lilly (NYSE:LLY) Touts Superior Results of Weight Loss Shot